From: Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
ClinicalTrials.gov identifier | Phase | Conditions | Drug classification | Interventions | Sponsors |
---|---|---|---|---|---|
NCT01996202 | Phase 1 | Melanoma | CTLA-4 inhibitors | Ipilimumab with radiation therapy | Duke University |
NCT02642809 | Phase 1 | EC | PD-1 inhibitors | Pembrolizumab with brachytherapy (16Â Gy in 2 fractions) | Washington University School of Medicine |
NCT02837263 | Phase 1 | Colorectal cancer | PD-1 inhibitors | Pembrolizumab with SBRT (40–60 Gy in 5 fractions) | University of Wisconsin, Madison |
NCT02587455 | Phase 1 | Thoracic tumors | PD-1 inhibitors | Arm I: pembrolizumab with low-dose radiation therapy Arm II: pembrolizumab with high-dose radiation therapy | Royal Marsden NHS Foundation Trust |
NCT03151447 | Phase 1 | TNBC | PD-L1 inhibitors | JS001 with SBRT | Fudan University |
NCT02868632 | Phase 1 | Pancreatic cancer | PD-L1 and CTLA-4 inhibitors | Durvalumab or/and tremelimumab with SBRT (30Â Gy in 5 fractions) | New York University School of Medicine |
NCT03275597 | Phase 1 | NSCLC | PD-L1 and CTLA-4 inhibitors | Durvalumab and tremelimumab with SBRT (30–50 Gy in 5 fractions) | University of Wisconsin, Madison |
NCT02239900 | Phase 1/2 | Liver cancer, lung cancer | CTLA-4 inhibitors | Ipilimumab with SBRT | M.D. Anderson Cancer Center |
NCT03050554 | Phase 1/2 | NSCLC | PD-L1 inhibitors | Avelumab with SBRT (48Â Gy in 4 fractions or 50Â Gy in 5 fractions) | Andrew Sharabi |
NCT02696993 | Phase 1/2 | Brain metastases (NSCLC) | PD-1 and CTLA-4 inhibitors | Arm I: nivolumab with stereotactic radiosurgery Arm II: nivolumab with whole brain radiation therapy Arm III: nivolumab and ipilimumab with stereotactic radiosurgeryArm IV: nivolumab and ipilimumab with whole brain radiation therapy | M.D. Anderson Cancer Center |
NCT01970527 | Phase 2 | Melanoma | CTLA-4 inhibitors | Ipilimumab with SBRT | University of Washington |
NCT02609503 | Phase 2 | Head and neck cancer | PD-1 inhibitors | Pembrolizumab with radiation therapy | UNC Lineberger Comprehensive Cancer Center |
NCT02730130 | Phase 2 | Metastatic breast cancer | PD-1 inhibitors | Pembrolizumab with radiation therapy | Memorial Sloan Kettering Cancer Center |
NCT02992912 | Phase 2 | Metastatic tumors | PD-L1 inhibitors | Atezolizumab with SBRT (45Â Gy in 3 fractions) | Gustave Roussy, Cancer Campus, Grand Paris |
NCT03122509 | Phase 2 | Metastatic colorectal cancer | PD-L1 and CTLA-4 inhibitors | Tremelimumab and durvalumab with radiation therapy | Memorial Sloan Kettering Cancer Center |
NCT02888743 | Phase 2 | Colorectal cancer and NSCLC | PD-L1 and CTLA-4 inhibitors | Arm I: tremelimumab and durvalumab Arm II: tremelimumab and durvalumab with high-dose radiation therapy Arm III: tremelimumab and durvalumab with low-dose radiation therapy | National Cancer Institute (NCI) |
NCT02701400 | Phase 2 | Recurrent SCLC | PD-L1 and CTLA-4 inhibitors | Arm I: tremelimumab and durvalumab Arm II: tremelimumab and durvalumab with SBRT | Emory University |
NCT02617589 | Phase 3 | Brain Cancer | PD-1 inhibitors | Arm I: nivolumab with radiation therapy Arm II: temozolomide with radiation therapy | Bristol-Myers Squibb |
NCT02768558 | Phase 3 | NSCLC | PD-1 inhibitors | Cisplatin and etoposide plus radiation followed by nivolumab | RTOG Foundation, Inc. |